Clinical Trials Directory

Trials / Completed

CompletedNCT01084486

Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
Sponsor
Wolfson Medical Center · Other Government
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis. Therefore, treatment of NAFLD with insulin sensitizers is likely to have a favorable effect towards hepatic steatosis and cardiovascular outcomes. Objectives: The present study investigated the effect of metformin on arterial properties, metabolic parameters and liver function in patients with NAFLD. Methods In randomized, placebo controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received placebo. Pulse wave velocity (PWV) and augmentation index (AI) were performed using SphygmoCor (version 7.1, AtCor Medical, Sydney, Australia) at baseline and at the end of 4-month treatment period.. Metabolic measures and serum adiponectin levels were determined.

Conditions

Interventions

TypeNameDescription
DRUGMetformin

Timeline

First posted
2010-03-10
Last updated
2010-03-10

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01084486. Inclusion in this directory is not an endorsement.

Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients (NCT01084486) · Clinical Trials Directory